SX682   Click here for help

GtoPdb Ligand ID: 10165

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: SX682 is a selective and reversible antagonist (negative allosteric modulator) of the C-X-C motif chemokine receptors CXCR1 and CXCR2. It is orally bioavailable and is being investigated for potential anti-inflammatory and antineoplastic activities. It was developed by Syntrix Pharmaceuticals. The chemical structure presented here was obtained from the NIH's NCI drug Dictionary
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 129.87
Molecular weight 467.07
XLogP 3.33
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)NC(=O)c1cnc(nc1)SCc1cc(ccc1B(O)O)OC(F)(F)F
Isomeric SMILES Fc1ccc(cc1)NC(=O)c1cnc(nc1)SCc1cc(ccc1B(O)O)OC(F)(F)F
InChI InChI=1S/C19H14BF4N3O4S/c21-13-1-3-14(4-2-13)27-17(28)12-8-25-18(26-9-12)32-10-11-7-15(31-19(22,23)24)5-6-16(11)20(29)30/h1-9,29-30H,10H2,(H,27,28)
InChI Key SDUDZBCEHIZMFZ-UHFFFAOYSA-N
Immunopharmacology Comments
SX682 is an orally bioavailable, selective and reversible negative allosteric modulator of the chemokine receptors for IL-8 (CXCL8), CXCR1 and CXCR2. It is being investigated principally as an antineoplastic immuno-oncology agent. SX682 inhibits the activation of CXCR1/2 by tumour-secreted chemokines, thus reducing the recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils to the tumour microenvironment (TME), which liberates effector cells (natural killer cells and cytotoxic T lymphocytes) to eliminate cancer cells.